OncoSec inks preclinical deal with Jounce Therapeutics

OncoSec Medical (NSDQ:ONCS) said today that it inked a preclinical deal with Jounce Therapeutics (NSDQ:JNCE) through the OncoSec Technology Access Program.

According to the agreement, Jounce will have access to OncoSec’s gene delivery technology to assess the efficacy of intratumorally-delivered therapeutic candidates. The deal includes OncoSec’s Genesis research generator, which features customizable electroporation parameters for construct-specific optimization of expression.

Get the full story at our sister site, Drug Delivery Business News.

The post OncoSec inks preclinical deal with Jounce Therapeutics appeared first on MassDevice.

from MassDevice http://ift.tt/2tif8vz